

The redesignation form consists of three parts:

- Part I - Institutional Profile**
- Part II - Terms of Reference (TOR)**
- Part III – Workplan**

**This redesignation form below, together with the Terms and conditions for WHO collaborating centres will serve as the agreement between the proposed institution and WHO if the redesignation as WHO collaborating centre is approved by WHO. Completion and submission of the redesignation form, however, does not guarantee that the designation will be approved.**

Folder eCC\_00020769 is in stage Form Completion (Institution)

<b>Name of the University, Hospital, Research Institute, Academy or Ministry</b>	
Iran University of Medical Sciences	
<b>Name of the Division, Department, Unit, Section or Area</b>	
School of Behavioural Sciences and Mental Health, Teheran Institute of Psychiatry	
<b>City</b>	<b>CC Reference Number</b>
Teheran	IRA-22
<b>Title</b>	
WHO Collaborating Centre for Mental Health	

**Part I - Institutional Profile**

The status of WHO CC is granted to an administrative unit of an institution (i.e. department, division or unit) and not to the institution as a whole in the vast majority of cases. For example, WHO CC status is granted to the Department of Microbiology of the University of ABC and not to the university itself. A WHO CC is not a legal entity. The legal entity is the proposed institution, i.e. the ministry, academy, university, established research institute or hospital, of a part thereof.

In the section entitled “sources of funding” some questions refer to the proposed terms of reference and activities included in the workplan of this proposal. Therefore please limit your responses to what is relevant in relation to the proposed terms of reference and activities included in the workplan.

However, when a question refers to the "proposed institution", please provide information on the legal entity as a whole (for example the University of ABC).

**Address of the proposed institution**

- |   |  |
|---|--|
| <b>1.1 Street and number</b>            | No1 Shahid Mansuri St., Niayesh St., Sattarkhan Ave. |
| <b>1.2 City</b>                         | Teheran  |
| <b>1.3 State/Region/Canton/Province</b> | Teheran  |
| <b>1.4 Postal Code</b>                  | 1445613111   |
| <b>1.5 Country</b>                      | IRA  |
| <b>1.6 WHO Region</b>                   | EMRO   |
| <b>1.7 Phone</b>                        | (98-21) 66513250                                     |



**1.8 Fax**

(98-21) 665 550200

**1.9 Web site**

<http://www.iums.ac.ir/>

**If you would like your institution to receive important news and other communications from WHO (unrelated to the work as a WHO CC) such as launching of new WHO campaigns, new WHO publications, etc, please indicate an email address.**

**Staff of the proposed institution**

**1.10 Name of the director of the institution as a whole**

Prof seyed kazem malakouti

**1.11 - Name and email of the proposed heads of the WHO collaborating centre (Please note this information will be listed in the public database)**

Salutation	First Name	Last Name	Email Address
Dr.	Seyed.Kazem	Malakouti	whocc.tip@iums.ac.ir
Salutation	First Name	Last Name	Email Address
	Mahmoud	Dehghani	

**1.12 Please list the names of professional who will work on the proposed terms of reference or activities of the workplan together with their professional qualifications (e.g. Dr John Smith MPH). Please do not include full resumes or biographies.**

- Dr. Seyed Vahid Shariat, psychiatrist
- Dr. Ahmad Hajebi, psychiatrist
- Dr. Maryam Rasoulia, psychiatrist
- Dr. Seyed Kazem Malakouti, psychiatrist
- Dr. Mohammadreza Shalbafan, psychiatrist
- Nafee Rasouli, psychologist, MS
- Dr. Sara Nooraeen, MD
- Dr. Shima Ataie, psychologist, PhD
- Dr. Mahdiah Salehi, psychiatrist
- Dr. Behin Araminia, psychiatrist
- Dr. Fahimeh Lavasani, psychologist, PhD
- Dr. Morteza Naserbakht, Social Medicine

**Sources of funding**

NOTE: Private-sector entities in this form refer to three categories: (i) business associations representing commercial enterprises, (ii) entities that are not at "arms' length" from their commercial sponsors, and (iii) partially or fully state-owned commercial enterprises that act like private-sector entities.

An entity that is "at arms' length" from another entity should meet the following three conditions: (i) to be financially and organizationally independent from the other entity, (ii) not to take instructions from the other entity, and (iii) not to be influenced or not reasonably perceived to be influenced in its decisions, activities, mandate and work by the other entity.



**1.13 During the last two years, what percentage of the funding of the proposed institution was core funding? Core funding refers to funding that is received regularly from secure sources, as opposed to ad-hoc contributions.**

over 75% regular (core) funding

**1.14 Please provide a complete list of donors that provide funding for the proposed institution, such as private-sector organizations, philanthropic foundations, nongovernmental organizations, governments, inter-governmental organizations and members of the public. Please include the full names of all donors, but not the amount donated.**

WHO, EMRO,  
WHO, Iran Office  
Ministry of Health and Medical Education, Mental Health Office

**1.15 Tobacco/arms-related disclosure statement .**

**Under the WHO Framework of Engagement with non-State Actors, WHO does not engage with the tobacco industry or non-State actors that work to further the interests of the tobacco industry. Moreover, WHO does not engage with the arms industry.**

**For the purposes of this statement: tobacco industry refers to any entity involved in the manufacture, sale or distribution of tobacco and related products, and any affiliate of such an entity; and arms industry refers to any entity involved in the manufacture, sale or distribution of arms, and any affiliate of such an entity.**

**To determine whether the proposed institution conforms to this rule, please answer the following questions:**

- **Is the proposed institution, or was the proposed institution over the last four years, part of the tobacco or arms industries (as defined above)?**
- **Is the proposed institution, or has the proposed institution over the last four years, engaged in activities that support the interests of the tobacco industry? This includes, but is not limited to, supply contracts, contract work, services and lobbying.**
- **Does the proposed institution currently, or did the proposed institution over the last four years, have any other association or relationship with the tobacco industry (as defined above)? This includes in particular investment interests (other than general mutual funds or similar arrangements whereby the institution has no control over the selection of the investments), commercial business interests, the provision or receipt of financial and/or other support.**
- **Does the proposed institution have any formal association, affiliation or links with private-sector entities and other non-State actors whose policies or activities negatively affect human health and are not in line with WHO's policies, norms and standards, in particular those related to noncommunicable diseases and their determinants?**

The answer is yes to at least one of the questions above. Please provide details

By selecting this choice I confirm that the answer to all the questions above is no

**[If yes] Please provide details (i.e. the names of entities, their activities, level of funding).**

**1.16 Is there any prospect that the proposed terms of reference or activities of the workplan will be funded by one or more private-sector entities that have, or may be perceived as having, a direct or indirect commercial interest in those proposed terms of reference or activities of the workplan?**

Yes  No

**[If yes] Please provide the names of these entities, their business activities and the level of funding.**

**1.17 Is any of the proposed terms of reference or activities of the workplan, or is there a prospect that any of the proposed terms of reference or activities of the workplan will be, performed as part of or related to work (research or other) commissioned by private-sector entities?**



Yes  No

**[If yes] Please provide the names of these entities, their business activities and the level of funding.**

**1.18 Is any of the proposed terms of reference or activities of the workplan, or is there a prospect that any of the proposed terms of reference or activities of the workplan will be, funded directly or indirectly by unspecified funds from one or more private-sector entities?**

Yes  No

**[If yes] Please provide the names of these entities, their business activities, level of funding, for what such funding is being, or will be, used and whether the implementation of the proposed terms of reference and activities of the workplan is dependent on the support of one or more of these private sector entities.**

**1.19 Are the salaries of staff who will work on the proposed terms of reference or activities of the workplan or their posts funded by one or more private sector entities, were they ever funded in this way in the past or could they receive such funding in future?**

Yes  No

**[if yes] Please provide the names of these entities, their business activities, level of funding, for which staff or what posts such funding is being, or will be, used, and the functions of such staff and/or posts.**

**1.20 Did over the last three years, does currently, or is there a prospect that, any specific staff who will work on the proposed terms of reference or activities of the workplan (including the proposed head(s) of the WHO collaborating centre), have any other interactions, affiliations or relations with, or any other personal, professional, financial or business interests in, one or more private sector entities that could give rise to a real or perceived conflict of interest or reputational risk?**

**Such risks may exist**

- (i) if the private sector entity has a direct or indirect commercial interest in all or part of the proposed terms of reference or activities of the workplan, or may be perceived as having such interest;**
- (ii) if the business activities of the entity engage with the tobacco industry and /or arms industry; or non-State actors that work to further the interests of the tobacco industry ; or**
- (iii) if the private sector entity has a vested interest in exerting influence on the proposed terms of reference or activities of the workplan and/or their outcome or may be seen as having such interest.**

**Interactions, affiliations, relations with, or other personal, professional, financial or business interests include, but are not necessarily limited to, collaborative projects or initiatives, employment, consultancy, investment interests (e.g. stocks, bonds, stock options, other securities, but not mutual funds, pension funds or similar investments that are broadly diversified), commercial business interests (e.g., proprietorships, partnerships, joint ventures), patents, trademarks, or copyrights (including pending applications), proprietary know-how in a substance, technology or process.**

Yes  No

**[if yes] Please provide details.**

**Institutional characteristics**



**1.21 What type of entity is the proposed institution?**

Public

**Please provide details**

University

**By ticking this box you confirm that the entity you represent is a nonprofit entity.**

**1.22 Please attach a current organizational chart (1 page) of the institution, including its administrative units such as divisions, departments, sections or areas (whichever structure applies), indicating the one proposed as WHO collaborating centre.**

TIP chart.pdf

**1.23 Please attach the constitutive documents of the institution you represent e.g. constitution, registration document, by-laws or similar.**

C1.PNG

**1.24 Number of years the institution is in operation.**

more than 10 years

**1.25 Please list major facilities and any specialized equipment available to the proposed institution (e.g. laboratories, training facilities, documentation centre), if applicable. Please do not list general office space or standard office equipment.**

1. computer network laboratory
2. one-way mirror room

**1.26 Does the proposed institution currently establish a smoke-free environment across its premises, which can be illustrated either through a documented institutional/departmental policy or through the existence of national/local smoke-free legislation? The smoke-free environment must apply to all indoor workplaces and public places of the institution's premises, and must entail a complete ban of smoking indoors and no areas designated for smoking.**

No

**I understand that information on my entity and its engagements with WHO that are categorized as public domain will be published in the WHO Register.**

**The proposed institution agrees with the following Terms and conditions for WHO collaborating centres.**

**Part II - Terms of Reference (TOR)**

Please include the proposed terms of reference for the future collaboration between the proposed institution and WHO, as discussed prior to completing this form. In most cases, 1-3 TOR will be sufficient to provide a high-level framework of the future collaboration. For redesignations, the current terms of reference is automatically prefilled but can be revised as appropriate.

For detailed instructions on how to fill in this section please click on the link provided at the top of the form.

**TOR 1** Under WHO's direction, support the integration of mental health into primary health care

**TOR 2** Upon request by WHO, scale up mental health services and build capacity of primary health care providers to deliver basic mental health services and interventions in line with the WHO mhGAP initiative.



**TOR 3** As requested by WHO, enhancing mental health literacy to reduce stigma and promote mental health and prevent mental disorders including suicide in countries of the Eastern Mediterranean region





<p><b>Activity ID</b> 30256</p>	<p><b>Activity title</b> Provide technical guidance on suicide prevention program development, implementation and evaluation in Countries of the Eastern Mediterranean region</p> <p><b>Link to TOR</b> TOR1</p> <p><b>Name(s) of responsible staff at the institution</b> Dr. Ahmad Hajebi, Dr. Seyed Kazem Malakouti</p> <p><b>Type of activity</b> Coordination of activities carried out by several institutions (e.g. other WHO collaborating centres)</p> <p><b>Why WHO is asking for this activity and how WHO will use the deliverables?</b> Integration of mental health component within PHC is one of the core strategies of WHO to enhance access to mental health care and reduce the treatment gap while Reduction in Suicide rates is one of the core indicators related to mental health both in GPW 13 and Global action plan for mental health in addition to being an indicator related to 3.4.1 SDG target .This will thus help WHO in reporting on the SDGs as well on the GPW 13 targets</p> <p><b>What concrete actions will be taken by the designated institution? Be specific.</b> Upon request by WHO, provide technical guidance to WHO on the development of national suicide prevention strategies/ programs in countries like Afghanistan, Pakistan, Syria, Tunisia and Iraq. Provide guidance on scale up of implementation of the Suicide prevention program in Iran for WHO's consideration</p> <p><b>What will be WHO's role in this activity?</b> WHO will lead the liaison with Member States and communicate requests from Member States as appropriate. Coordination and technical support for development of national policies and programs, dissemination/sharing of information to MS as WHO deems appropriate</p> <p><b>Expected deliverables</b> A report provided each year on the technical guidance provided to WHO on the setup of national suicide prevention programs in Countries of EMR and Evaluation of Suicide prevention programs</p> <p><b>Intellectual property rights</b> IP rights of ALL deliverables belong to the WHOCC as per paragraphs 3.1.1 and/or 3.2.1 of the Terms and Conditions</p> <p><b>Name(s) of funding sources</b> Institution's budget, WHO may partially contribute to this activity</p> <p><b>Activity timeframe</b> July 2020- December 2024</p> <p><b>This activity has been specifically developed for the workplan of the WHO collaborating centre and does not constitute a standard activity of the institution without WHO involvement.</b></p>
---------------------------------	---





<p><b>Activity ID</b> 30257</p>	<p><b>Activity title</b> Conduct research to reduce stigma associated with mental health and minimize discrimination faced by persons with mental health problems</p> <p><b>Link to TOR</b> TOR3</p> <p><b>Name(s) of responsible staff at the institution</b> Dr. Mohammadreza Shalbafan and Dr Behin Araminia</p> <p><b>Type of activity</b> Research</p> <p><b>Why WHO is asking for this activity and how WHO will use the deliverables?</b> Stigma is an overarching problem with its attendant discrimination contributes to perpetuation of outdated models of care, minimal allocation of resources for mental health and human right abuses. The result is a massive treatment gap for mental health problems despite availability of cost effective and affordable interventions. The research will be considered by WHO in WHO's development of a regional action plan and initiatives to address the issue of stigma and discrimination in countries of the region. By identifying and removing the barriers of establishing and expanding the cost-effective mental health services, this activity is related to mental health both in GPW 13 and Global action plan for mental health in addition to being an indicator related to 3.4.1 SDG target.</p> <p><b>What concrete actions will be taken by the designated institution? Be specific.</b> Literature review about the cost effective anti-stigma interventions for WHO's consideration in the development of a regional action plan for reducing stigma and promoting Public mental health literacy</p> <p><b>What will be WHO's role in this activity?</b> WHO will provide advice on the technical requirements and knowledge gaps to guide the development of the literature review</p> <p><b>Expected deliverables</b> Literature review on mental health stigma, (cultural believes, barriers against the provision of mental health services, public and policy makers attitude), cost-benefit interventions. and providing practical guides for further planning and implementation of anti-stigma programs in the member states of the region</p> <p><b>Intellectual property rights</b> IP rights of ALL deliverables belong to the WHOCC as per paragraphs 3.1.1 and/or 3.2.1 of the Terms and Conditions</p> <p><b>Name(s) of funding sources</b> The Institution's Budget</p> <p><b>Activity timeframe</b> September 2020 -- December 2024</p> <p><b>This activity has been specifically developed for the workplan of the WHO collaborating centre and does not constitute a standard activity of the institution without WHO involvement.</b></p>
---------------------------------	--



<p><b>Activity ID</b> 30258</p>	<p><b>Activity title</b> Using e-health technology for suicide prevention</p> <p><b>Link to TOR</b> TOR1</p> <p><b>Name(s) of responsible staff at the institution</b> Dr. Seyed Kazem Malakouti; Ms. Nafee Rasouli, Dr. Sara Nooraeen</p> <p><b>Type of activity</b> Development and application of appropriate technology</p> <p><b>Why WHO is asking for this activity and how WHO will use the deliverables?</b> Reduction in Suicide rates is one of the core indicators related to mental health both in GPW 13 and Global action plan for mental health in addition to being an indicator related to 3.4.1 SDG target.WHO will be able to benefit from this development to scale up Suicide prevention activities and overcome the socio cultural barriers</p> <p><b>What concrete actions will be taken by the designated institution? Be specific.</b> Lead the development of e-health technology platform for suicide prevention which can be used by Farsi language countries like Afghanistan and Tajikistan in the short term and support the adaptation of the platform for use in other countries .</p> <p><b>What will be WHO's role in this activity?</b> technical support for development of instruments for suicide prevention and guidance to evaluate the efficacy and cost-benefit of this platform.</p> <p><b>Expected deliverables</b> Suicide prevention intervention platform Efficacy and cost effectiveness study</p> <p><b>Intellectual property rights</b> IP rights of ALL deliverables belong to the WHOCC as per paragraphs 3.1.1 and/or 3.2.1 of the Terms and Conditions</p> <p><b>Name(s) of funding sources</b> Iran University of Medical Sciences, deputy of research and Iranian Scientific Society for Suicide Prevention, WHO depending on availability of resources might contribute</p> <p><b>Activity timeframe</b> September 2020 -- December 2024</p> <p><b>This activity has been specifically developed for the workplan of the WHO collaborating centre and does not constitute a standard activity of the institution without WHO involvement.</b></p>
---------------------------------	---



<p><b>Activity ID</b> 30259</p>	<p><b>Activity title</b> scaling up the capacity of general health care personnel to deliver basic mental health services and intervention in line with the mhGAP initiative of WHO</p> <p><b>Link to TOR</b> TOR2</p> <p><b>Name(s) of responsible staff at the institution</b> Dr. Maryam Rasoulia, Dr. Shima Ataie</p> <p><b>Type of activity</b> Support WHO in the implementation of WHO programmes and activities at country level</p> <p><b>Why WHO is asking for this activity and how WHO will use the deliverables?</b> Early diagnosis and management of priority mental health problems through PHC and FPs is one of the key interventions identified by WHO in bridging the treatment gap and enhancing access to mental health care. For this purpose WHO has launched the mhGAP initiative in 2008 and is developed the mhGAP-IG with its suite of implementation support tools and instruments. It is a flagship program of WHO and is part of the DGs special initiative on mental health. It is in line both GPW 13 and Global action plan for mental health</p> <p><b>What concrete actions will be taken by the designated institution? Be specific.</b> Upon request by WHO: Contextualization of mhGAP -IG for Farsi speaking countries Provide technical expertise on the conduct of mhGAP-IG Training of Trainers and Supervisors (ToTs). As and when appropriate, provide technical support on the roll out of mhGAP program in Iran and neighboring countries like Afghanistan, Tajikstan, Pakistan</p> <p><b>What will be WHO's role in this activity?</b> WHO will lead the liaison with Member States and communicate requests from Member States as appropriate. Technical support and coordination across countries in EMR and across WHO regions</p> <p><b>Expected deliverables</b> mhGAP-IG appropriate for FARSI-speaking countries. Report on guidance provided on ToT and mhGAP roll out. Improved the quality of PHC network by scaling up the capacity of PHC personnel and FPs for early recognition and management of priority mental disorders</p> <p><b>Intellectual property rights</b> IP rights of ALL deliverables belong to WHO as per paragraphs 3.1.2 and/or 3.2.2 of the Terms and Conditions</p> <p><b>Name(s) of funding sources</b> Institution's core budget. Ministry of Health, Mental Health Bureau</p> <p><b>Activity timeframe</b> October 2020-- December 2024</p> <p><b>This activity has been specifically developed for the workplan of the WHO collaborating centre and does not constitute a standard activity of the institution without WHO involvement.</b></p>
---------------------------------	---



<p><b>Activity ID</b> 30260</p>	<p><b>Activity title</b> Promoting mental health literacy at national and regional levels</p> <p><b>Link to TOR</b> TOR3</p> <p><b>Name(s) of responsible staff at the institution</b> Dr. Fahimeh Lavasani, Dr. Seyed Vahid Shariat</p> <p><b>Type of activity</b> Support WHO in the implementation of WHO programmes and activities at country level</p> <p><b>Why WHO is asking for this activity and how WHO will use the deliverables?</b> Increasing mental health literacy is very important in reducing discrimination and providing adequate care. This needs a whole of society approach to have extensive impact on the society. This is in line of GPW 13 and Global action plan for mental health</p> <p><b>What concrete actions will be taken by the designated institution? Be specific.</b> Literature review to find effective interventions for increasing mental health literacy. Support adaptation of the interventions to local contexts Support implementing the interventions in collaboration of all stakeholders . Evaluation of the effectiveness of the implemented measures.</p> <p><b>What will be WHO's role in this activity?</b> Technical support on developing the evaluation plan as well as technical advice on adaptation of interventions.</p> <p><b>Expected deliverables</b> Literature review Locally adapted interventions deliverable to different sub-populations  Increased mental health literacy and reduced stigma in target population groups .</p> <p><b>Intellectual property rights</b> IP rights of ALL deliverables belong to the WHOCC as per paragraphs 3.1.1 and/or 3.2.1 of the Terms and Conditions</p> <p><b>Name(s) of funding sources</b> Institution's core budget. Ministry of Health, Mental Health Bureau. WHO</p> <p><b>Activity timeframe</b> September 2020-- December 2024</p> <p><b>This activity has been specifically developed for the workplan of the WHO collaborating centre and does not constitute a standard activity of the institution without WHO involvement.</b></p>
---------------------------------	--



<p><b>Activity</b> ID 30261</p>	<p><b>Activity title</b> Support the third party evaluation of the national mental health programmes</p> <p><b>Link to TOR</b> TOR2</p> <p><b>Name(s) of responsible staff at the institution</b> Dr Ahmed Hajebi, Dr. Seyed Vahid Shariat, Dr. Morteza Naserbakht</p> <p><b>Type of activity</b> Support WHO in the implementation of WHO programmes and activities at country level</p> <p><b>Why WHO is asking for this activity and how WHO will use the deliverables?</b> WHO is seeking to conduct an independent evaluation of the national mental health programmes in countries of EMR .The evaluation will be helpful to develop a standardized methodology as well as instruments.This is further useful to showcase the national mental health programmes and WHO to use as a case study for the other countries and regions to implement similar activities</p> <p><b>What concrete actions will be taken by the designated institution? Be specific.</b> Identification of the evaluation methodology with WHO Identification/Modification of technical tools for evaluation based on available instruments from WHO Data collection, processing and analysis Support the development of the evaluation report and case study Development of report on findings, data, methodology, and analysis for WHO's consideration</p> <p><b>What will be WHO's role in this activity?</b> Technical support in developing evaluation methodology, identification of instruments/ tools and consultants to undertake the evaluation Validation of the case study/ report. WHO will lead the liaison with Member States and communicate requests from Member States as appropriate</p> <p><b>Expected deliverables</b> Evaluation report for the national mental health programmes and case study</p> <p><b>Intellectual property rights</b> IP rights of ALL deliverables belong to WHO as per paragraphs 3.1.2 and/or 3.2.2 of the Terms and Conditions</p> <p><b>Name(s) of funding sources</b> The Institution's Budget</p> <p><b>Activity timeframe</b> October 2020-- December 2024</p> <p><b>This activity has been specifically developed for the workplan of the WHO collaborating centre and does not constitute a standard activity of the institution without WHO involvement.</b></p>
-------------------------------------	---